Evidence map›Paper›PMID 39046786›Full record

ArticleBlood2024

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Yanli Zhang, Na Xu, Robert Peter Gale, Weiming Li, Xiaoli Liu, Huanling Zhu, Ling Pan and 38 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. [Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Guideline
  2. Article
  3. Article
  4. Article
  5. Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.Clinical pharmacology : advances and applications · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

48 authors.

Xiaoshuai ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Bingcheng LiuNational Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China.
Jian HuangDepartment of Hematology, The First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Zhejiang, China.ORCID 0000-0003-4200-8636
Yanli ZhangDepartment of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Henan, China.
Na XuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Robert Peter GaleDepartment of Immunology and Inflammation, Centre for Hematology, Imperial College London, London, United Kingdom.ORCID 0000-0002-9156-1676
Weiming LiDepartment of Hematology, Union hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China.
Xiaoli LiuDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Huanling ZhuDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan, China.
Ling PanDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan, China.
Yunfan YangDepartment of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan, China.ORCID 0000-0002-2924-7002
Hai LinDepartment of Hematology, The First Hospital of Jilin University, Jilin, China.
Xin DuDepartment of Hematology, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Rong LiangDepartment of Hematology, Xijing Hospital, Airforce Military Medical University, Xi'an, China.
Chunyan ChenDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Xiaodong WangDepartment of Hematology, Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Sichuan, China.
Guohui LiDepartment of Hematology, Xi'an international medical center hospital, Xi'an, China.
Zhuogang LiuDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
Yanqing ZhangShenzhen Hospital of Southern Medical University, Shenzhen, China.ORCID 0000-0003-0156-699X
Zhenfang LiuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China.
Jianda HuDepartment of Hematology, The Second Affiliated Hospital of Fujian Medical University, Fujian, China.
Chunshui LiuDepartment of Hematology, The First Hospital of Jilin University, Jilin, China.
Fei LiCenter of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Wei YangDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
Li MengDepartment of Hematology, Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Yanqiu HanDepartment of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China.ORCID 0000-0002-2658-0803
Li'e LinDepartment of Hematology, Hainan General Hospital, Hainan, China.
Zhenyu ZhaoDepartment of Hematology, Hainan General Hospital, Hainan, China.
Chuanqing TuDepartment of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China.
Caifeng ZhengDepartment of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China.
Yanliang BaiDepartment of Hematology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan, China.
Zeping ZhouDepartment of Hematology, The Second Hospital Affiliated to Kunming Medical University, Kunming, China.
Suning ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Soochow, China.ORCID 0000-0001-6294-972X
Huiying QiuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Soochow, China.
Lijie YangDepartment of Hematology, Xi'an international medical center hospital, Xi'an, China.
Xiuli SunDepartment of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Hui SunDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Li ZhouShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zelin LiuDepartment of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen, China.
Danyu WangDepartment of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen, China.
Jianxin GuoDepartment of Hematology, The Second Affiliated Hospital of Fujian Medical University, Fujian, China.
Liping PangDepartment of Hematology, Peking University Shenzhen Hospital, Shenzhen, China.
Qingshu ZengDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, China.ORCID 0000-0002-6887-5255
Xiaohui SuoDepartment of Hematology, Handan Central Hospital, Handan, China.
Weihua ZhangDepartment of Hematology, First Hospital of Shanxi Medical University, Shanxi, China.
Yuanjun ZhengDepartment of Hematology, First Hospital of Shanxi Medical University, Shanxi, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Qian JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.ORCID 0000-0001-7131-0522

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractAlthough tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20% to 30% of people still experienced therapy failure. Data from 1955 consecutive patients with chronic-phase CML diagnosed by the European LeukemiaNet recommendations from 1 center receiving initial imatinib or a second-generation (2G) TKI therapy were interrogated to develop a clinical prediction model for TKI-therapy failure. This model was subsequently validated in 3454 patients from 76 other centers. Using the predictive clinical covariates associated with TKI-therapy failure, we developed a model that stratified patients into low-, intermediate- and high-risk subgroups with significantly different cumulative incidences of therapy failure (P < .001). There was good discrimination and calibration in the external validation data set, and the performance was consistent with that of the training data set. Our model had the better prediction discrimination than the Sokal and European Treatment and Outcome Study long-term survival scores, with the greater time-dependent area under the receiver-operator characteristic curve values and a better ability to redefine the risk of therapy failure. Our model could help physicians estimate the likelihood of initial imatinib or 2G TKI-therapy failure in people with chronic-phase CML.

Indexed as

Imatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsTreatment FailureAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesFemaleHumansMaleMiddle AgedPiperazinesPrognosisAntineoplastic AgentsBenzamidesImatinib MesylatePiperazinesProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrimidinesTyrosine Kinase Inhibitors

Identifiers

PMID39046786
PMCPMC11551847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.